Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H A Burris

Showing results (61-70 of 114) with videos related to

Pageof 12
Sort By:
Cancer Journal (Sudbury, Mass.)|July 6, 2000
Paclitaxel, carboplatin, and vinorelbine in the treatment of advanced non-small cell lung cancer: a phase II trial of the Minnie Pearl Cancer Research NetworkJ D Hainsworth, H A Burris, L H Morrissey, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 13, 2000
Carcinoma of unknown primary site: phase II trials with docetaxel plus cisplatin or carboplatinF A Greco, J B Erland, L H Morrissey, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 16, 2001
Paclitaxel and gemcitabine chemotherapy for advanced transitional-cell carcinoma of the urothelial tract: a phase II trial of the Minnie pearl cancer research networkA A Meluch, F A Greco, H A Burris, et al.
Anti-Cancer Drugs|October 1, 1994
Phase I clinical trial of ormaplatin (tetraplatin, NSC 363812)T J O'Rourke, G R Weiss, P New, et al.
Anti-Cancer Drugs|August 1, 1992
A phase I clinical and pharmacokinetic study of the topoisomerase I inhibitor topotecan (SK&F 104864) given as an intravenous bolus every 21 daysJ G Wall, H A Burris, D D Von Hoff, et al.
Anti-Cancer Drugs|August 1, 1994
Phase I and pharmacokinetic studies of topotecan administered as a 72 or 120 h continuous infusionH A Burris, A Awada, J G Kuhn, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 24, 2013
Optimally tolerated dose of lapatinib in combination with docetaxel plus trastuzumab in first-line treatment of HER2-positive metastatic breast cancerJ Crown, M J Kennedy, P Tresca, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 29, 1998
Phase I clinical and pharmacologic study of eniluracil plus fluorouracil in patients with advanced cancerR L Schilsky, J Hohneker, M J Ratain, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1994
Phase I clinical trial of gemcitabine given as an intravenous bolus on 5 consecutive daysT J O'Rourke, T D Brown, K Havlin, et al.
Investigational New Drugs|September 18, 1998
Pharmacokinetic and phase I studies of brequinar (DUP 785; NSC 368390) in combination with cisplatin in patients with advanced malignanciesH A Burris, E Raymond, A Awada, et al.
Pageof 12

Showing results (61-70 of 114) with videos related to

Sort By:
Pageof 12
Cancer Journal (Sudbury, Mass.)|July 6, 2000
Paclitaxel, carboplatin, and vinorelbine in the treatment of advanced non-small cell lung cancer: a phase II trial of the Minnie Pearl Cancer Research NetworkJ D Hainsworth, H A Burris, L H Morrissey, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 13, 2000
Carcinoma of unknown primary site: phase II trials with docetaxel plus cisplatin or carboplatinF A Greco, J B Erland, L H Morrissey, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 16, 2001
Paclitaxel and gemcitabine chemotherapy for advanced transitional-cell carcinoma of the urothelial tract: a phase II trial of the Minnie pearl cancer research networkA A Meluch, F A Greco, H A Burris, et al.
Anti-Cancer Drugs|October 1, 1994
Phase I clinical trial of ormaplatin (tetraplatin, NSC 363812)T J O'Rourke, G R Weiss, P New, et al.
Anti-Cancer Drugs|August 1, 1992
A phase I clinical and pharmacokinetic study of the topoisomerase I inhibitor topotecan (SK&F 104864) given as an intravenous bolus every 21 daysJ G Wall, H A Burris, D D Von Hoff, et al.
Anti-Cancer Drugs|August 1, 1994
Phase I and pharmacokinetic studies of topotecan administered as a 72 or 120 h continuous infusionH A Burris, A Awada, J G Kuhn, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 24, 2013
Optimally tolerated dose of lapatinib in combination with docetaxel plus trastuzumab in first-line treatment of HER2-positive metastatic breast cancerJ Crown, M J Kennedy, P Tresca, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 29, 1998
Phase I clinical and pharmacologic study of eniluracil plus fluorouracil in patients with advanced cancerR L Schilsky, J Hohneker, M J Ratain, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1994
Phase I clinical trial of gemcitabine given as an intravenous bolus on 5 consecutive daysT J O'Rourke, T D Brown, K Havlin, et al.
Investigational New Drugs|September 18, 1998
Pharmacokinetic and phase I studies of brequinar (DUP 785; NSC 368390) in combination with cisplatin in patients with advanced malignanciesH A Burris, E Raymond, A Awada, et al.
Pageof 12